AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03963960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis with low dialysate flow
Description: Hemodialysis with low dialysate flow
Study NCT03963960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional triweekly high-flow hemodialysis
Description: Conventional triweekly high-flow hemodialysis
Study NCT06567600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody
Description: Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met.
Study NCT06568289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: A perineal infiltration of a 5-ml of the drug (100 mg of lignocaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
Study NCT06568289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: A perineal infiltration of a 5-ml of the study drug (20 mg of Bupivacaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
Study NCT05518058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: device and exercises
Description: device and exercises
Study NCT06250660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry Intervention
Description: This is an intervention based on the intake of strawberry, specifically the Fortuna variety. This intervention is based on the intake of 250 g of fresh strawberries per day for a month. The amount and duration of strawberry intake has been consulted in other studies carried out with strawberries.
Study NCT04937413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab subcutaneous injection
Study NCT06483009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation: For subjects assessed as stable disease (SD) after two cycles of medication, one session is performed under local anesthesia after assessment. The multidisciplinary team, including investigators and radiologists, evaluates the feasibility of tumor ablation based on the size, location, and proximity to major blood vessels. Criteria for eligible lesions include a maximum diameter \<5cm, relatively isolated lesion location, and not adjacent to major blood vessels or vital structures. Cryoablation is performed using a 17G IceRod Plus 1.5 cryoablation needle, guided by CT, and avoiding nearby anatomical structures using the Visual-ICE cryoablation system.
Study NCT04241588 — intervention group
Intervention type: DEVICE
Intervention: 3D Printed Upper-limb Prosthesis
Description: The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging the structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post-manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion. The device will be given to participants so that they may practice using the device at home.
Study NCT04241588 — intervention group
Intervention type: OTHER
Intervention: Control
Description: A 3D printed hand with be fitted to simulate a prosthesis.
Study NCT05234801 — intervention group
Intervention type: DEVICE
Intervention: DARCO™ Headed Cannulated Screw
Description: The DARCO™ Headed Cannulated Screw is a multi-size screw system designed to be used over a guide pin or wire with instrumentation to provide interfragmentary compression and stability for bone fracture/fragment fixation.
Study NCT05234801 — intervention group
Intervention type: DEVICE
Intervention: ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System
Description: A multi-indication foot reconstruction solution providing indication specific implants and instruments designed to address the unique demands of the forefoot and midfoot.
Study NCT05234801 — intervention group
Intervention type: DEVICE
Intervention: ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module
Description: A comprehensive fixation system consisting of a wide variety of plate options, created with the purpose of stabilization and fixation of fractures, revision procedures, joint fusion and reconstruction of small bones of the feet.
Study NCT05255731 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency laser activated photobiomodulation
Description: Protocol description Infrared: analgesia, biostimulation of tissues, edema and hyperemia (hard and soft tissues). There will be 11 laser application points, 3 intra-oral and 8 extra-oral, with a total dose of 33J.~Intraoral: one point in the region of the mandibular lingula (point of submersion of the mandibular nerve), one vestibular point and one lingual point in relation to the alveolus of the extracted wisdom tooth.~Extraoral: for muscle relaxation, five points on the masseter muscle; for oedema drainage, one point in each lymph node region: parotid, submandibular and buccal.
Study NCT05255731 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low frequency laser photobiomodulation inactive
Description: The same protocol as the activated group
Study NCT06389578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Description: SC administration and IV infusion
Study NCT05503186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: The intervention consists of a series of text messages aimed to facilitate secure storage and disposal of unused opioid medications.
Study NCT05503186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Information provided by the physician and/or pharmacist.
Study NCT05503186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Information provided by the physician and/or pharmacist.
Study NCT06063694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic electrospun fiber matrix
Description: Electrospun fiber matrices have long been investigated as an innovative construct for use in tissue engineering and regenerative medicine research due to their ability to mimic the structure and scale of native tissue. Clinical studies have demonstrated clinical efficacy in treating both chronic and acute wounds. There is strong evidence to support the application of a synthetic electrospun fiber matrix will generate favorable wound healing and reduce infection rates when used to augment transmetatarsal amputation.
Study NCT04870905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tis-U-Sol
Description: Tislelizumab 200mg will be given every 3 weeks for 12 cycles
Study NCT06060847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome
Description: Patients in the experimental arm will undergo liver resection for HCC and sleeve gastrectomy for MS during the same surgical procedure.
Study NCT06060847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection for HCC induced by metabolic syndrome
Description: Patients in the active comparator arm will undergo liver resection for HCC
Study NCT06439524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
Description: if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis
Study NCT04948138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine oral supplementation
Description: Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
Study NCT04894617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine
Description: 200 mg Amantadine daily for a total of 5 days.
Study NCT04894617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose monohydrate
Description: Lactose monohydrate two tablet daily for a total of 5 days.
Study NCT05599035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repititive transcranial magnetic stimulation
Description: a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
Study NCT05599035 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repititive transcranial magnetic stimulation
Description: a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
Study NCT05018572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I AM
Description: I am has a biopsychosocial perspective with a focus on pain management in migraines. The cognitive behavioural interventions being tested are Mindfulness, Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy and Physiotherapist-led cardiotherapy. The treatment program consists of ten modules of texts, animated films with a fictional person to identify with, recorded audio exercises adapted for patients with migraines and filmed physiotherapeutic exercises with physiotherapists.The interventions in I am are personalised in that the first three modules and module 10 are for those who are being helped by a shorter treatment. The other modules, four to ten, are a more in-depth treatment for those who have frequent or chronic migraines. The participants are in contact with processors via message function as well as via phone at startup, at the middle of treatment and termination. The duration of treatment is 4-10 weeks.
Study NCT04978792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-compassion intervention
Description: An online self-guided intervention that uses widely available exercises and information.
Study NCT06584786 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Jing Si herbal tea (JSHT)
Description: JSHT has been approved by the Ministry of Health and Welfare of Taiwan (registration number MOHW-PM-060635).
Study NCT06584786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of JSHT
Study NCT04978792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will complete written exercises and breathing exercises that are not associated with self-compassion
Study NCT06048484 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: SBRT 40 gray (Gy) over 5 fractions
Study NCT06048484 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiotherapy (SBRT)
Description: SBRT 40 gray (Gy) over 5 fractions
Study NCT05019872 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.
Study NCT06117436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 100 MG oral tablet once daily antiplatelet, Selenium 200mcg tablet once daily, anti oxidant
Study NCT06117436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: Selenium 200 mcg oral tablet once daily
Study NCT06048484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: 240 mg intravenously (IV)
Study NCT06048484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zimberelimab
Description: 240 mg intravenously (IV)
Study NCT06106048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises
Description: Group A was treated with closed kinetic chain exercises. Group A: Group A was treated with closed kinetic chain exercises. Closed kinetic chain exercises enhance the proprioception by coordinating the mechanical receptors as well as the strength of the external shoulder rotator muscles, reduce the pain and improve the shoulder.~Closed kinetic chain exercises include:~* Push up~* Scapular push up~* Scapular dip~* Crab walk~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280, wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week.
Study NCT06106048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal contraction exercises
Description: Group B was treated with abdominal contraction exercises for periscapular activation that includes: Wall slide, knee pushup, external rotation kneeling, Full can and External rotation with elevation and isometric low row.~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280,wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week.
Study NCT06465329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous (IV) infusion administration
Study NCT06465329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cemiplimab
Description: Intravenous (IV) infusion administration
Study NCT06465329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: IV infusion
Study NCT06465329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-based chemotherapy
Description: IV infusion
Study NCT06465329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7075
Description: IV infusion
Study NCT05488639 — intervention group
Intervention type: OTHER
Intervention: Registration of football exposure and occurrence of injuries and illnesses only
Description: Injury \& illness registration~Data on injury and illness is gathered following the recommended methodology in the football extension of the International Olympic Committee consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport. This includes characteristics such as mode of onset, injury mechanism, diagnosis and classification according to body area, tissue, and pathology type, and illness categories for organ system and etiology. Time-loss will be counted in number of days.
Study NCT04909593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Spinal cord stimulation at varied electrode, pulse width, frequency and amplitude parameters
Study NCT05672862 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: PCI was performed using drug-eluting stents
Study NCT04113226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.
Study NCT04113226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.
Study NCT04113226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 20 MG
Description: patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with Rituximab plus Lenalidomide. Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression
Study NCT04113226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Geriatric Assessment (CGA)
Description: A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,...) on which treatment may impact.
Study NCT04113226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Description: A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,...) on which treatment may impact.
Study NCT04113226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activities of daily living (ADL) scale
Description: Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
Study NCT04113226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADL) scale
Description: Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
Study NCT05483478 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: mobile health combined Multi-course Program
Description: mobile health combined Multi-course Program
Study NCT05483478 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mobile health combined Multi-course Program
Description: mobile health combined Multi-course Program
Study NCT05844982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faricimab
Description: 6.0 mg intravitreal injection at randomization and every 3 months
Study NCT05844982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluocinolone acetonide
Description: 0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
Study NCT05424952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversational AI Service (Chatbot)
Description: WhatsApp or Messenger Chatbot for COVID-19 vaccines
Study NCT05363839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-000029
Description: ACH-000029 will be administered orally via a capsule.
Study NCT05363839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally via a capsule.
Study NCT04867551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: oral administration, dose titration
Study NCT05048316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Stress Management and Health Education
Description: Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
Study NCT04830579 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etoricoxib film-coated tablet 120 mg
Description: Etoricoxib is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 120 mg of etoricoxib.
Study NCT04830579 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Arcoxia® film-coated tablet 120 mg
Description: Arcoxia® is manufactured by Frosst Iberica SA, Spain. Each tablet contains 120 mg of etoricoxib.
Study NCT04472949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: 1500 mg iv
Study NCT04472949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin: AUC 5 mg/mL/min iv
Study NCT04472949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Etoposide: 100 mg/m2 iv